Molecular imaging with FAPI for diagnosing the CSM4 colorectal cancer subtype

2023-509183-17-00 Protocol U23-0607 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 1 Aug 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol U23-0607

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 45
Countries 1
Sites 1

Colorectal cancer, liver metastases

Key facts

Sponsor
Universitair Medisch Centrum Utrecht
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06], Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Trial duration
1 Aug 2024 → ongoing
Decision date (initial)
2024-03-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Colorectal cancer, liver metastases

VersionLevelCodeTermSystem organ class
21.0 PT 10052358 Colorectal cancer metastatic 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitair Medisch Centrum Utrecht

Sponsor organisation
Universitair Medisch Centrum Utrecht
Address
Heidelberglaan 100
City
Utrecht
Postcode
3584 CX
Country
Netherlands

Scientific contact point

Organisation
Universitair Medisch Centrum Utrecht
Contact name
M. van Duijvenvoorde

Public contact point

Organisation
Universitair Medisch Centrum Utrecht
Contact name
M. van Duijvenvoorde

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 45 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Universitair Medisch Centrum Utrecht
Nuclear Medicine, Heidelberglaan 100, 3584 CX, Utrecht

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-08-01 2025-02-07

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-01 Netherlands Acceptable with conditions
2024-03-22
2024-03-27
2 SUBSTANTIAL MODIFICATION SM-2 2025-07-22 Netherlands Acceptable
2025-09-12
2025-09-12